Draft remit: To appraise the clinical and cost effectiveness of NBTXR-3 within its CE marked indication for neoadjuvant treatment of soft tissue sarcoma.
Status In progress
Process STA pre-2018
ID number 1050

Provisional Schedule

The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of NBTXR-3 for treating soft tissue sarcoma ID1050. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this proposed appraisal. The consultation on the draft scope closed on Tuesday 19 December 2017. After careful review of the consultation comments received NICE has agreed that a scoping workshop would not be appropriate. As a consequence of this the scoping workshop arranged for Thursday 11 January 2018 at 14:00.has been cancelled. NICE will still submit a report to the Department of Health summarising the results of the consultation. The report will help ministers to decide whether or not the technology should be formally referred to NICE for appraisal. If you have any comments or concerns please contact the project manager for this proposed appraisal Michelle Adhemar via email at michelle.adhemar@nice.org.uk 21 December 2018

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
21 November 2017 - 19 December 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
11 August 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance